This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Souli, M.
Right arrow Articles by Giamarellou, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Souli, M.
Right arrow Articles by Giamarellou, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 1998, p. 939-941, Vol. 42, No. 4
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Effects of Slime Produced by Clinical Isolates of Coagulase-Negative Staphylococci on Activities of Various Antimicrobial Agents

Maria Soulidagger and Helen Giamarellou*

First Department of Propedeutic Medicine, Laiko General Hospital, Athens University School of Medicine, Athens, Greece

Received 7 July 1997/Returned for modification 20 November 1997/Accepted 6 February 1998

A novel in vitro semiquantitative method was developed to investigate the influence of staphylococcal slime on the activities of 22 antimicrobial agents. Pefloxacin, teicoplanin, and vancomycin demonstrated remarkable decreases in efficacy: 30, 52, and 63%, respectively. The activity of rifampin was not significantly reduced (0.99%), whereas all other agents tested were modestly affected (<15% decrease). These data could be influential in the treatment of implant-associated infections caused by slime-producing staphylococci.

* Corresponding author. Mailing address: First Department of Propedeutic Medicine, Laiko General Hospital, 17 Agiou Thoma str., GR 115 27 Athens, Greece. Phone: (301) 7790802. Fax: (301) 7709447. E-mail: vatmsidl{at}hol.gr.

dagger Present address: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115.

Antimicrobial Agents and Chemotherapy, April 1998, p. 939-941, Vol. 42, No. 4
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Lynch, S. V., Dixon, L., Benoit, M. R., Brodie, E. L., Keyhan, M., Hu, P., Ackerley, D. F., Andersen, G. L., Matin, A. (2007). Role of the rapA Gene in Controlling Antibiotic Resistance of Escherichia coli Biofilms. Antimicrob. Agents Chemother. 51: 3650-3658 [Abstract] [Full Text]  
  • Al-Fattani, M. A., Douglas, L. J. (2006). Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance.. J Med Microbiol 55: 999-1008 [Abstract] [Full Text]  
  • Labthavikul, P., Petersen, P. J., Bradford, P. A. (2003). In Vitro Activity of Tigecycline against Staphylococcus epidermidis Growing in an Adherent-Cell Biofilm Model. Antimicrob. Agents Chemother. 47: 3967-3969 [Abstract] [Full Text]  
  • Gentilini, E., Denamiel, G., Betancor, A., Rebuelto, M., Fermepin, M. R., De Torres, R. A. (2002). Antimicrobial Susceptibility of Coagulase-Negative Staphylococci Isolated from Bovine Mastitis in Argentina. J DAIRY SCI 85: 1913-1917 [Abstract] [Full Text]  
  • Donlan, R. M., Costerton, J. W. (2002). Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms. Clin. Microbiol. Rev. 15: 167-193 [Abstract] [Full Text]  
  • Krzywda, E. A., Andris, D. A., Edmiston, C. E. Jr (1999). Catheter Infections: Diagnosis, Etiology, Treatment, and Prevention. Nutr Clin Pract 14: 178-190 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»